Does CANAKINUMAB Cause Interstitial lung disease? 201 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 201 reports of Interstitial lung disease have been filed in association with CANAKINUMAB (Ilaris). This represents 1.9% of all adverse event reports for CANAKINUMAB.
201
Reports of Interstitial lung disease with CANAKINUMAB
1.9%
of all CANAKINUMAB reports
66
Deaths
121
Hospitalizations
How Dangerous Is Interstitial lung disease From CANAKINUMAB?
Of the 201 reports, 66 (32.8%) resulted in death, 121 (60.2%) required hospitalization, and 106 (52.7%) were considered life-threatening.
Is Interstitial lung disease Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for CANAKINUMAB. However, 201 reports have been filed with the FAERS database.
What Other Side Effects Does CANAKINUMAB Cause?
Pyrexia (1,327)
Inappropriate schedule of drug administration (1,238)
Drug ineffective (1,078)
Inappropriate schedule of product administration (944)
Pain (858)
Condition aggravated (771)
Malaise (684)
Off label use (557)
Arthralgia (555)
Rash (505)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PEMBROLIZUMAB (2,113)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
NIVOLUMAB (1,538)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
Which CANAKINUMAB Alternatives Have Lower Interstitial lung disease Risk?
CANAKINUMAB vs CANDESARTAN
CANAKINUMAB vs CANDESARTAN CILEXETIL
CANAKINUMAB vs CANDESARTAN CILEXETIL\HYDROCHLOROTHIAZIDE
CANAKINUMAB vs CANGRELOR
CANAKINUMAB vs CANIS LUPUS FAMILIARIS SKIN